Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.58 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589086 | 0.93 | MEN1 (0.63) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL109414 | 0.92 | LTA4H (0.57) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL730251 | 0.89 | NR5A1 (0.63) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL3058202 | 0.87 | NR5A1 (0.67) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL3056357 | 0.87 | NR5A1 (0.67) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL3044803 | 0.87 | NR5A1 (0.67) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL10427931 | 0.87 | NR5A1 (0.67) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL14546295 | 0.87 | NR5A1 (0.67) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL728423 | 0.87 | NR5A1 (0.67) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL3051144 | 0.87 | NR5A1 (0.67) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9701626-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2016-01-14 | — | — | US | disclosed |
| US-9169201-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2786985-A2 | Antagonists of the glucagon receptor | Metabasis Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2129654-B1 | ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | METABASIS THERAPEUTICS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | ALDH1A1 4642/4885SMN1; SMN2 4026/4885MEN1 2416/4885 |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | ALDH1A1 4642/4885SMN1; SMN2 4026/4885MEN1 2416/4885 |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | GLP1R, GCGR, GPR119 | ALDH1A1 4642/4885SMN1; SMN2 4026/4885MEN1 2416/4885 |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | ALDH1A1 4642/4885SMN1; SMN2 4026/4885MEN1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.